<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626972</url>
  </required_header>
  <id_info>
    <org_study_id>2020-001599-13</org_study_id>
    <nct_id>NCT05626972</nct_id>
  </id_info>
  <brief_title>Tenecteplase Compared to Alteplase for Patients With Large Vesel Oclusion Suspicion Before Thrombectomy</brief_title>
  <official_title>A Multi-center, Randomized, Open-label Blinded Endpoint (PROBE), Phase III Study, for the Comparation of Tenecteplase (TNK) Versus Alteplase, With a 1:1 Allocation, Before Thrombectomy in Patients With Acute Ischemic Stroke and Large Vessel Occlusion Suspicion in Catalonia (TNK-CAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: The TNKCAT trial represents an innovative approach to optimize timely reperfusion&#xD;
      in the Mothership and Drip-and-Ship scenarios. The logistic advantage of a single bolus&#xD;
      infusion of TNK (compared to 1-h infusion of tPA) would markedly reduce the needle-to-groin&#xD;
      and Door-in- door-out time. The implementation of a quality improvement package (QIP) in the&#xD;
      TNKCAT trial would directly improve the quality and efficiency of the Health Care System. In&#xD;
      addition, an improvement of transfer models would reduce the cost of unnecessary transfers,&#xD;
      together with the fact that TNK is up to 50% less expensive than tPA, makes the TNKCAT in&#xD;
      firm line with the sustainability strategy of the National Health Care system.&#xD;
&#xD;
      Outcomes: The aim of the present study is to determine the safety and efficacy of TNK&#xD;
      (0.25mh/kg) compared to tPA (0.9 mg/kg) in patients with Large Vessel Occlusion (LVO)&#xD;
      suspicion, candidates for thrombectomy, in both Mothership and Drip-and-Ship scenarios.&#xD;
&#xD;
      Study Duration: 2 years. Patients will participate in the trial for 3 months.&#xD;
&#xD;
      Study design: Multicentre, prospective, randomized open-label blinded endpoint (PROBE) phase&#xD;
      III study in acute stroke patients with LVO suspicion within 4.5 hours of stroke onset,&#xD;
      candidates for EVT. Patients will be randomized 1:1 to standard dose tPA (0.9 mg/kg) or TNK&#xD;
      (0.25mg/kg) before EVT.&#xD;
&#xD;
      Clinical, imaging and outcome data will be collected at baseline, 24-36 hours, day 3, day 5&#xD;
      and day 90.&#xD;
&#xD;
      Estimated enrollment: 500 patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2022</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Clinical outcome at day 90 will be obtained by centralized telephone call of the mRS in a blinded manner by certified personnel of the Catalan Stroke Program.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin scale score at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Shift analysis of the modified Rankin scale score at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>3 months</time_frame>
    <description>Mortality at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatic intracerebral haemorrhage (ICH) and neurological deterioration</measure>
    <time_frame>24 -36hours</time_frame>
    <description>Symptomatic ICH defined as intracerebral haemorrhage (PH2) within 36 hours of treatment, combined with neurological deterioration leading to an increase of ≥ 4 points on the National institute of Health Stroke Scale (NIHSS) from baseline, or the lowest NIHSS value between baseline and 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of mRS 0-1 at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Modified Rankin scale score (0-1) rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of mRS 0-2 at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Modified Rankin scale score (0-2) rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of pre-interventional recanalization</measure>
    <time_frame>during the procedure</time_frame>
    <description>Recanalization rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dramatic clinical recovery before endovascular treatment (EVT)</measure>
    <time_frame>before the procedure</time_frame>
    <description>Dramatic clinical recovery before EVT (Improvement in &gt; 8 points in the NIHSS score or NIHSS score &lt; 2 before groin puncture)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First pass TICI 3, final TICI 2b-3</measure>
    <time_frame>immediately after the procedure</time_frame>
    <description>Rates of first pass TICI 3, final TICI 2b-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal embolization during EVT</measure>
    <time_frame>during the procedure</time_frame>
    <description>Rates of distal embolization during EVT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needle-to-groin times and DIDO times</measure>
    <time_frame>immediately after the procedure</time_frame>
    <description>Differences in needle-to-groin times in Mothership patients and in DIDO times in Drip-and-Ship patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time metrics between TNKCAT and non-TNKCAT centers</measure>
    <time_frame>at the end of the study</time_frame>
    <description>Differences in time metrics between TNKCAT and non-TNKCAT centers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final infarct volume on follow up CT</measure>
    <time_frame>24-36 hours follow up</time_frame>
    <description>Differences in final infarct volume on follow up CT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Tenecteplase (TNK)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Alteplase (tPA) Dose: 0.9 mg/kg Route: Intravenous (IV) infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alteplase (tPA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Tenecteplase (TNK) Dose: 0.25 mg/kg Route: Intravenous (IV) bolus injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>Patients will be randomized 1:1 to standard dose tPA (0.9 mg/kg) or TNK (0.25mg/kg) before endovascular therapy (EVT)</description>
    <arm_group_label>Alteplase (tPA)</arm_group_label>
    <arm_group_label>Tenecteplase (TNK)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients eligible to undergo intravenous thrombolysis (tPA or TNK) within 4.5 hours&#xD;
             after the onset of ischemic stroke.&#xD;
&#xD;
          -  Suspicion of Cerebral vascular occlusion on brain imaging.&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
          -  Men and women (women with child-bearing potential are excluded, unless pregnancy test&#xD;
             negative/ confirmed menstrual period/ postmenopausal or hysterectomy).&#xD;
&#xD;
          -  A new focal disabling neurologic deficit consistent with acute cerebral ischemia.&#xD;
&#xD;
          -  Informed consent obtained from subject or acceptable subject surrogate (i.e. next of&#xD;
             kin, or legal representative), or Differed Inform Consent (DIC) to avoid any delay in&#xD;
             the initiation of iv thrombolysis. The DIC will be sign by the patient or next of kin&#xD;
             at any time after the tPA or TNK treatment is started.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients with severe preexisting disability, defined as a modified Rankin scale score&#xD;
             &gt;3.&#xD;
&#xD;
          -  Glasgow Coma Scale score ≤ 7.&#xD;
&#xD;
          -  Known hemorrhagic diathesis, coagulation factor deficiency, or antivitamin K oral&#xD;
             anticoagulant therapy with INR &gt;3.0. Subjects on factor Xa inhibitors (e.g. apixaban)&#xD;
             or direct thrombin inhibitors are eligible for participation.&#xD;
&#xD;
          -  Severe, sustained and uncontrollable hypertension (systolic blood pressure &gt;185 mmHg&#xD;
             or diastolic blood pressure &gt;110 mmHg).&#xD;
&#xD;
          -  Serious, advanced, or terminal illness with anticipated life expectancy of less than 3&#xD;
             months.&#xD;
&#xD;
          -  Patients that are unlikely to be available for a 90-day follow-up (e.g. no fixed home&#xD;
             address, visitor from overseas).&#xD;
&#xD;
          -  Patient participating in a randomized study, involving an investigational drug or&#xD;
             device that would impact this study.&#xD;
&#xD;
          -  Suspicion of aortic dissection presumed septic embolus, or suspicion of bacterial&#xD;
             endocarditis.&#xD;
&#xD;
        Imaging exclusion criteria:&#xD;
&#xD;
          -  Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.&#xD;
&#xD;
          -  Cerebral vasculitis.&#xD;
&#xD;
          -  CT or MRI evidence of hemorrhage&#xD;
&#xD;
          -  Significant mass effect with midline shift.&#xD;
&#xD;
          -  Evidence of intracranial tumor.&#xD;
&#xD;
          -  Subjects with known occlusions in multiple vascular territories (e.g., bilateral&#xD;
             anterior circulation, or anterior/posterior circulation).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlos Molina, Dr</last_name>
    <phone>(+34) 93 489 30 00</phone>
    <phone_ext>4996</phone_ext>
    <email>cmolina@vhebron.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Molina, Dr.</last_name>
      <phone>(+34) 93 489 30 00</phone>
      <phone_ext>4996</phone_ext>
      <email>cmolina@vhebron.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 22, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2022</study_first_posted>
  <last_update_submitted>November 22, 2022</last_update_submitted>
  <last_update_submitted_qc>November 22, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <keyword>large vessel occlusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

